Comments

Eisai Co

ESALFOTCPK

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

$38.21

00.00%

Last update: Sep 19, 1:33 PM

15 minutes delayed

Eisai Co (ESALF) Forecast

News Earnings Guidance Dividends Analyst Ratings Insider Trades Short Interest

Eisai Co (OTC:ESALF) Stock Quotes, Forecast and News Summary

Eisai Co Stock (OTC: ESALF) stock price, news, charts, stock research, profile.

Open	-
Close	-
Volume / Avg.	2.96K / 779.00
Day Range	- - -
52 Wk Range	30.23 - 60.00
Market Cap	$10.81B
P/E Ratio	47.65
Dividend Yield	2.68%
Exchange	OTC
RSI	0
Short Interest	-
Days to Cover	999.99

Recent News

Biogen's Alzheimer's Drug Secures UK Approval, But An Independent Agency Does Not Recommend Reimbursement

The U.K.'s Medicines and Healthcare products Regulatory Agency approved Eisai and Biogen's Leqembi for treating mild cognitive impairment and mild dementia due to Alzheimer's. Despite this, NICE stated the drug's benefits are too small to justify the cost for NHS use.

Vandana Singh

Biogen/Eisai's Alzheimer's Drug Leqembi Gets 'No Go' From European Drug Regulator's Advisory Panel, Cites Serious Side Events

The European Medicines Agency's CHMP has rejected the approval of Eisai and Biogen's Alzheimer's treatment lecanemab, citing concerns over its risks. Eisai plans to appeal the decision and work towards making the treatment available in the EU, where Alzheimer's affects 6.9 million people.

Vandana Singh

Bernie Sanders: 'Getting Sick In America Should Not Mean Going Bankrupt, Losing Your Home, Car, Or Life Savings'

Benzinga Neuro

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

About

Sector

Healthcare

Industry

N/A

Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists ...

Compare

EPS better than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.